




# Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) for Cardiogenic Shock

Dr. Fausto Biancari
Clinica Montevergine, GVM Care and Research,
Mercogliano

## What is a cardiogenic shock?

It is the inability of
the heart to maintain an effective cardiac output
commensurate to the metabolic demands of
the body attributable to a primary underlying
cardiac pathology

## **Causes of cardiogenic shock**



## **Definition criteria of cardiogenic shock**

#### Clinical Features of Cardiogenic Shock and Defined Contemporary Trials and Guidelines

Clinical Trial/ Guidelines	Cardiogenic Shock Criteria
SHOCK Trial (1999)	<ul> <li>SBP&lt;90 mm Hg or vasopressor support to maintain SBP &gt;90 mm Hg</li> <li>Evidence of end-organ damage (UO&lt;30 ml/h or cool extremities)</li> </ul>
	<ul> <li>Hemodynamic criteria: CI&lt;2.2 and PCWP&gt;15 mmHg</li> </ul>
IABP-SOAP II (2012)	<ul> <li>MAP &lt; 70 mm Hg or SBP &lt; 100 mm Hg despite adequate fluid resuscitation (at least 1 L of crystalloid or 500 ml of colloids)</li> </ul>
	<ul> <li>Evidence of end-organ damage (AMS, mottled skin, UO &lt; 0.5 ml/kg/h for 1 h or serum lactate &gt;2 mmol/L)</li> </ul>
EHS-PCI (2012)	<ul> <li>SBP &lt; 90 mm Hg for 30 min or inotropes use to maintain SBP &gt; 90 mm Hg</li> </ul>
	Evidence of end-organ damage and increased filling pressure
ESC-HF Guidelines	<ul> <li>SBP&lt;90 mmHg with appropriate fluid resuscitation with clinical and laboratory evidence of end-organ damage</li> </ul>
(2016)	<ul> <li>Clinical: cold extremities, oliguria, AMS, narrow pulse pressure. Laboratory: metabolic acidosis, elevated serum lactate, elevated serum creatinine</li> </ul>
KAMIR-NIH (2018)	SBP < 90 mm Hg for > 30 min or supportive intervention to maintain SBP > 90 mm Hg
10-1011 (2010)	<ul> <li>Evidence of end-organ damage (AMS, UO &lt; 30 ml/h, or cool extremities)</li> </ul>

#### **CLINICAL DECISION MAKING**

WILEY

#### SCAI clinical expert consensus statement on the classification of cardiogenic shock

This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019

Extremis

Stage E "Extremis". A patient with circulatory collapse, frequently (but not always) in refractory cardiac arrest with ongoing cardiopulmonary resuscitation (CPR) or are being supported by multiple simultaneous acute interventions including ECMOfacilitated CPR. These are patients with multiple clinicians at bedside laboring to address multiple simultaneous issues related to the lack of clinical stability of the patient.

Deteriorating

Stage D "Deteriorating or Doom". A patient that is similar to category C but is getting worse. They have failure to respond to initial interventions.

Classic


Stage C "Classic" Cardiogenic Shock. A patient that manifests with hypoperfusion that requires intervention (inotrope, pressor or mechanical support, ECMO) beyond volume resuscitation to restore perfusion. These patients typically present with relative hypotension.

**Beginning** 

Stage B "Beginning" Cardiogenic Shock. A patient who has clinical evidence of relative hypotension or tachycardia without hypoperfusion.

At Risk


Stage A "At Risk". A patient who is not currently experiencing signs or symptoms of cardiogenic shock, but is at risk for its development. These patients may include those with acute myocardial infarction, acute and/or acute on chronic heart failure symptoms.



<sup>\*</sup>Implications of time delay incurred during MCS initiation before primary reperfusion therapy are uncertain pending dedicated trials in the setting of cardiogenic shock complicating AMI.

## 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)






#### AHA SCIENTIFIC STATEMENT

# Invasive Management of Acute Myocardial Infarction Complicated by Cardiogenic Shock

A Scientific Statement From the American Heart Association

Circulation. 2021;143:e815-e829.



## <u>Circulation</u>

#### AHA SCIENTIFIC STATEMENT

# Invasive Management of Acute Myocardial Infarction Complicated by Cardiogenic Shock

A Scientific Statement From the American Heart Association

Circulation. 2021;143:e815-e829.

Patients presenting in shock (stages C–E) may first require acute stabilization with attention to blood pressure, endorgan perfusion status, oxygenation, and acid-base status.

Especially in cases of STEMI, any necessary stabilization efforts must be expedited to minimize delay to reperfusion therapy




### AHA SCIENTIFIC STATEMENT


# Invasive Management of Acute Myocardial Infarction Complicated by Cardiogenic Shock

A Scientific Statement From the American Heart Association

Circulation. 2021;143:e815-e829.




## Main mechanical circulatory support strategies for cardiogenic shock




## Mechanical circulatory support strategies for right ventricular failure

## **Direct RV Bypass**


Indirect RV Bypass







Tandem RVAD



Protek Duo



VA-ECMO

**Axial Flow** 

Extracorporeal Centrifugal Flow


## What is a VA-ECMO?

V-A support is the application of ECC primarily for cardiocirculatory or cardiopulmonary support, in which the extracorporeal circuit drains blood from the venous system and returns it to the systemic arterial system oxygenated and normalized for pCO<sub>2</sub>

## The ELSO Maastricht Treaty for ECLS Nomenclature

Modes Flow direction, from → ML→ to		VV (ECMO) V-V, VV-V V-V		VA (ECMO)	VVA (ECMO)			AV (ECCO <sub>2</sub> R)
				V-A, VV-A	V-VA	V-VA V-AV		A-V
Configuration		Single-lumen cannulae	Dual-lumen cannula	Single-lumen cannulae	Single-lumen cannulae from V- V	Dual-lumen cannula from V- V	Single-lumen cannulae from V-A	Single-lumen cannulae
Level 1: Hierarchy	Upper case = major flow cannula Lower case = minor flow cannula	Vcep-V	(dl)V-V, (ca)V-V, (bc)Vcep-V	V-Ad, (dl)VV-Ad	Vv-VAd	(dl)V-VA	V-AdV	(pl)A-V
Level 2: Cannulation site	Indexed	V <sub>f</sub> -V <sub>j</sub>	(dl)V <sub>f</sub> -V, (ca)V <sub>j</sub> cep-V	$V_j$ - $A_f$ , $V_j$ $V_f$ - $A_f$ d, $V_j$ - $A_{car}$	V <sub>f</sub> -V <sub>j</sub> A <sub>f</sub>	(bc)V <sub>j</sub> -VA <sub>f</sub> d	$V_j$ - $A_fV_f$	(pl)A <sub>fl</sub> -V <sub>fr</sub>
Level 3: Tip position	Indexed	V <sub>ivc</sub> -V <sub>a</sub> , V <sub>ja</sub> cep-V <sub>f</sub>	V <sub>fsvc</sub> -V <sub>f</sub>	V <sub>ja</sub> -A <sub>fli</sub> d <sub>p</sub> vnt <sub>al,</sub> V <sub>ja</sub> -A <sub>srg</sub> , V <sub>j</sub> -A <sub>i</sub>	$V_f$ - $V_{fivc}A_f$ , $V_f$ - $V_jA_i$	(ca)V <sub>j</sub> -VA <sub>sic</sub>	V <sub>ja</sub> v <sub>c</sub> -A <sub>fr</sub> d <sub>p</sub> V <sub>fr</sub>	(pl)A <sub>fri</sub> -V <sub>fli</sub>
Level 4: Cannula dimension	OD/L, L is never given unless OD first	V21/50-V17, V21 <sub>f</sub> - V17 <sub>fivc</sub> V23/25 <sub>a</sub> - V17 <sub>f</sub>	(dl31)V-V, (ca32)V <sub>j</sub> cep-V	V25/25-A17/18, V29 <sub>fa</sub> - A <sub>f</sub> d <sub>t</sub> V25 <sub>fisvc</sub> -A <sub>fi</sub> 19d <sub>p</sub>	V25/38 <sub>j</sub> -V <sub>f</sub> A19/18 <sub>f</sub> d <sub>t</sub>	(dl23)V-VA <sub>f</sub>	V25/25 <sub>ja</sub> v <sub>a</sub> - A21 <sub>fr</sub> d <sub>p</sub> V17/50 <sub>fr</sub>	(pI)A15/17 <sub>fr</sub> - V15 <sub>fl</sub>


## Main configurations of VA-ECMO




Peripheral VA-ECMO


Central VA-ECMO


## Other configurations of VA-ECMO



## Externalizations of central VA-ECMO







Peripheral VA-ECMO

# Decision Making in Adult VA-ECMO for Acute Cardiac Failure


VA ECMO may support patients for days or weeks as a "bridge-to-decision" that includes weaning after recovery of cardiac function, transplantation, long-term mechanical circulatory support (ventricular assist devices), and withdrawal in the case of futility

# When to use and not use VA-ECMO for cardiogenic shock?

## ELSO Interim Guidelines for Venoarterial Extracorporeal Membrane Oxygenation in Adult Cardiac Patients

ROBERTO LORUSSO®,\* KIRAN SHEKAR,† GRAEME MACLAREN®,‡ MATTHIEU SCHMIDT,§ VINCENT PELLEGRINO,¶
BART MEYNS|| JONATHAN HAFT,# LEEN VERCAEMST,|| FEDERICO PAPPALARDO,\*\*\* CHRISTIAN BERMUDEZ,††
JAN BELOHLAVEK®,‡‡ XIAOTONG HOU,§§ UDO BOEKEN,¶¶ ROBERTO CASTILLO,|| || DIRK W. DONKER®,##\*\*\*
DARRYL ABRAMS,††† MARCO RANUCCI,‡‡‡ KASIA HRYNIEWICZ,§§§ IVAN CHAVEZ,§§§ YIH-SHARNG CHEN,¶¶¶
LEONARDO SALAZAR,|| || || AND GLENN WHITMAN###

REVIEWERS: Hergen Buscher,\*\*\*\* Rodrigo Diaz,†††† Thomas Mueller,‡‡‡‡ AND Alain Combes,§§§§



ASAIO Journal 2021 Guidelines

## ELSO Interim Guidelines for Venoarterial Extracorporeal Membrane Oxygenation in Adult Cardiac Patients

ROBERTO LORUSSO<sup>®</sup>,\* KIRAN SHEKAR,† GRAEME MACLAREN<sup>®</sup>,‡ MATTHIEU SCHMIDT,§ VINCENT PELLEGRINO,¶
BART MEYNS || JONATHAN HAFT,# LEEN VERCAEMST, || FEDERICO PAPPALARDO,\*\* CHRISTIAN BERMUDEZ,††
JAN BELOHLAVEK<sup>®</sup>,‡‡ XIAOTONG HOU,§§ UDO BOEKEN,¶¶ ROBERTO CASTILLO, || || DIRK W. DONKER<sup>®</sup>,##\*\*\*
DARRYL ABRAMS,††† MARCO RANUCCI,‡‡‡ KASIA HRYNIEWICZ,§§§ IVAN CHAVEZ,§§§ YIH-SHARNG CHEN,¶¶¶
LEONARDO SALAZAR, || || || AND GLENN WHITMAN###

REVIEWERS: Hergen Buscher,\*\*\*\* Rodrigo Diaz,†††† Thomas Mueller,‡‡‡ AND Alain Combes,§§§§

# Cardiogenic shock suitable for ECMO is generally characterized by:

- systemic systolic pressure less than 90 mmHg
- urine output < 30 ml/hour</li>
- lactate over 2
- SVO<sub>2</sub> less than 60%
- altered conscious state for 6 hours
- unresponsive to optimal treatment

#### 2020 EACTS/ELSO/STS/AATS Expert Consensus on Post-Cardiotomy

## Extracorporeal Life Support in Adult Patients

Roberto Lorusso, MD, PhD, Chairperson,\* Glenn Whitman, MD, Chairperson,\* Milan Milojevic, MD, PhD,\* Giuseppe Raffa, MD, PhD, David M. McMullan, MD, Udo Boeken, MD, PhD, Jonathan Haft, MD, Christian A. Bermudez, MD, Ashish S. Shah, MD, and David A. D'Alessandro, MD

Check for updates

Recommendations for Indications, Contraine Prognostication of PC-ECLS	dications	s and
Recommendations	Class <sup>a</sup>	Level
It is recommended that PC support be initiated prior to end-organ injury or onset of anerobic metabolism (lactate level <4 mmol/l) in patients with likelihood of myocardial recovery and in the absence of uncontrollable bleeding not amenable to surgical repair. <sup>14,33</sup>	I	В
When the likelihood of native myocardial recovery is low, PC ECLS is recommended in patients who are eligible for LT-MCS or a HTx.	Ι	С
The early use of ECLS after cardiac surgery in a patient with an IABP and optimal medical therapy, with failure to wean from CPB or marginal hemodynamics is recommended. <sup>33</sup>	I	В
Significant comorbidities, advanced age, elevated lactate level and renal injury are risk factors associated with death and should be considered prior to ECLS initiation. <sup>25,27,33</sup>	IIa	В
Preoperative implant of ECLS may be considered in patients in very poor condition (hemodynamic or metabolic) or with structural cardiac anomalies (postacute MI VSD, severe lung edema or dysfunction due to underlying cardiac disease) to facilitate perioperative management (bridge to surgery).	IIb	С
It should be considered that the type and modality of ECLS (uni or biventricular failure, right or left ventricular compromise, preoperative, intraoperative or postoperative cardiocirculatory failure, acute or chronic cardiac dysfunction, cardiogenic shock or cardiac arrest, including alternative mechanical support device) are discussed based on the type of hemodynamic condition and patient characteristics.	IIa	С

## ELSO Interim Guidelines for Venoarterial Extracorporeal Membrane Oxygenation in Adult Cardiac Patients

ROBERTO LORUSSO<sup>©</sup>, \* KIRAN SHEKAR,† GRAEME MACLAREN<sup>©</sup>, ‡ MATTHIEU SCHMIDT, \$ VINCENT PELLEGRINO, ¶
BART MEYNS || JONATHAN HART, # LEEN VERCAEMST, || FEDERICO PAPPALARDO, \*\* CHRISTIAN BERMUDEZ,††
JAN BELOHLAVEN<sup>©</sup>, ‡‡ XIAOTONG HOU, \$\$ UDO BOEKEN, ¶ ¶ ROBERTO CASTILLO, || || DIRK W. DONKER<sup>©</sup>, ##\*\*\*
DARRYL ABRAMS,††† MARCO RANUCCI, ‡‡‡ KASIA HRYNIEWICZ, \$\$\$ IVAN CHAVEZ, \$\$\$ YIH-SHARNG CHEN, ¶ ¶ ¶
LEONARDO SALAZAR, || || || AND GIENN WHITMAN###

REVIEWERS: Hergen Buscher,\*\*\*\* Rodrigo Diaz,†††† Thomas Mueller,‡‡‡‡ AND Alain Combes,\$§§§

Table 2. The SAVE Score<sup>6</sup>

Parameter		Score				
Acute cardiogenic shock o	liagnosis group					
(select one or more)	nagricolo group					
Myocarditis		3				
Refractory VT/VF		2				
Post heart or lung transp	olantation	3				
Congenital heart disease		2 3 -3				
	Other diagnoses leading to cardiogenic					
shock requiring VA EC		0				
Age (yrs)	DIVIO					
18–38		7				
39–52		4				
53–62		3				
55 <b>-</b> 62 ≥63		0				
Weight (kg)		U				
×veignt (kg) ≤65		1				
65–89		2				
≥90		0				
Acute pre-ECMO organ fai	ilures	Ü				
(select one or more if						
Liver failure*		-3				
Central nervous system	−3 −3 −3					
Renal failure‡	-3					
Chronic renal failure§	-6					
Duration of intubation befor	e initiation of ECMO (h)					
≤10	( )	0				
11–29		-2				
≥30		-4				
Peak inspiratory pressure:	≤20 cmH <sub>o</sub> O	3 -2 3 -2				
Pre-ECMO cardiac arrest	2	-2				
Diastolic blood pressure bef	ore ECMO ≥ 40 mmHa¶	3				
Pulse pressure before ECN		-2				
HCO₃ before ECMO ≤15 m		-3 -6				
Constant value to add to a	all calculations	-6				
of SAVE score						
Total score		-35 to 17				
Total SAVE score	Risk class	Survival (%)				
>5		75				
1–5	ii .	58				
-4 to 0	iii	42				
-9 to -5	iV	30				
≤ −10	V	18				

#### ELSO Interim Guidelines for Venoarterial Extracorporeal Membrane Oxygenation in Adult Cardiac Patients

ROBERTO LORUSSO<sup>©</sup>, \* Kiran Shekar,† Graeme MacLaren<sup>©</sup>, ‡ Matthieu Schmidt, § Vincent Pellegrino, ¶
Bart Meyns || Jonathan Hart, # Leen Vercaemst, || Federico Pappalardo, \*\*\* Christian Bermudez,††
Jan Belohlavek<sup>©</sup>,‡‡ Xiaotong Hou, §§ Udo Boeken, ¶¶ ¶ Roberto Castillo, || || Dirk W. Donker<sup>©</sup>, ##\*\*\*
Darryl Abrams,††† Marco Ranucc,‡‡‡ Kasia Hryniewicz, §§§ Ivan Chavez, §§§ Yih-Sharng Chen, ¶¶¶
Leonardo Salazar, || || || and Genn Whitman###

REVIEWERS: Hergen Buscher.\*\*\*\* Rodrigo Diaz, ++++ Thomas Mueller, ++++ AND Alain Combes, \$\\$\\$

- Cardiac recovery unlikely and no indication for heart transplant or durable left ventricular (LV) assists device
- Poor life expectancy (end-stage peripheral-organ diseases, malignant tumor, massive pulmonary embolisms in cancer patients, chemotherapy-induced chronic cardiomyopathy, etc.)
- Severe aortic valve regurgitation
- Severe vascular disease with extensive aortic and peripheral vessel involvement (calcification, stenosis, and closure), including axillary arteries
- Acute Type A or B aortic dissection with extensive aortic branches (ascending, supra-aortic and femoral) involvement (preoperatively)
- Severe neurologic impairment (i.e., prolonged anoxic brain damage, extensive trauma and bleeding)
- Severe immunologic disease with marked blood and coagulation disorders
- Liver cirrhosis (Child-Pugh class B and C)

## Early invasive therapy in comatose patients with out-ofhospital cardiac arrest can be contraindicated in case of:

- An initial nonshockable rhythm
- Unwitnessed arrest
- Lack of bystander cardiopulmonary resuscitation
- >30 min to return of spontaneous circulation or ongoing CPR
- pH <7.2
- Lactate >7 mmol/L
- Age >85 years
- End-stage renal disease
- Noncardiac cause of arrest

American College of Cardiology. Cardiac arrest: a treatment algorithm for emergent invasive cardiac procedures in the resuscitated comatose patient. J Am Coll Cardiol. 2015;66:62–73.


#### ADULT: MECHANICAL CIRCULATORY SUPPORT

## Multicenter study on postcardiotomy venoarterial extracorporeal membrane oxygenation



Fausto Biancari, MD, PhD, a,b Magnus Dalén, MD, PhD, Antonio Fiore, MD, Vito G. Ruggieri, MD, PhD, Diyar Saeed, MD, Kristján Jónsson, MD, PhD, Giuseppe Gatti, MD, Svante Zipfel, MD, Andrea Perrotti, MD, PhD, Karl Bounader, MD, Antonio Loforte, MD, PhD, Andrea Lechiancole, MD, Marek Pol, MD, Cristiano Spadaccio, MD, Matteo Pettinari, MD, Sigurdur Ragnarsson, MD, PhD, Khalid Alkhamees, MD, Giovanni Mariscalco, MD, PhD, and Henryk Welp, MD, the PC-ECMO Study Group

J Thorac Cardiovasc Surg 2020;159:1844-54



# PC-ECMO risk score Age 60-69 years 2 ≥70 years 4 Female gender 1 Prior cardiac surgery 1 Arterial lactate ≥6 mmol/L 2 Aortic arch surgery 4 Stroke/unconsciousness 5

## ELSO Interim Guidelines for Venoarterial Extracorporeal Membrane Oxygenation in Adult Cardiac Patients

ROBERTO LORUSSO®,\* KIRAN SHEKAR,† GRAEME MACLAREN®,‡ MATTHIEU SCHMIDT,§ VINCENT PELLEGRINO,¶
BART MEYNS|| JONATHAN HAFT,# LEEN VERCAEMST,|| FEDERICO PAPPALARDO,\*\* CHRISTIAN BERMUDEZ,††
JAN BELOHLAVEK®,‡‡ XIAOTONG HOU,§§ UDO BOEKEN,¶¶ ROBERTO CASTILLO,||| DIRK W. DONKER®,##\*\*\*
DARRYL ABRAMS,††† MARCO RANUCCI,‡‡‡ KASIA HRYNIEWICZ,§§§ IVAN CHAVEZ,§§§ YIH-SHARNG CHEN,¶¶¶
LEONARDO SALAZAR,||||| AND GIENN WHITMAN###

REVIEWERS: Hergen Buscher,\*\*\*\* Rodrigo Diaz,†††† Thomas Mueller,‡‡‡‡ AND Alain Combes,§§§§

The goal of VA-ECMO is to maintain systemic oxygen delivery at least 3 times oxygen consumption (the DO2:VO2 ratio is >3) (normal DO2:VO2 ratio is 5, in shock is 2)



ROBERTO LORUSSO®,\* KIRAN SHEKAR,† GRAEME MACLAREN®,‡ MATTHIEU SCHMIDT,§ VINCENT PELLEGRINO,¶

BART MEYNS∥ JONATHAN HART,# LEEN VERCAEMST,∥ FEDERICO PAPRALARDO,\*\* € CHRISTIAN BERMUDEZ,††

JAN BELOHLAVEK®,‡‡ XIAOTONG HOU,§§ UDO BOEKEN,¶¶ ROBERTO CASTILLO,∥∥ DIRK W. DONKER®,##\*\*\*

DARRYL ABRAMS,††† MARCO RANUCCI,‡‡‡ KASIA HRYNIEWICZ,§§§ IVAN CHAVEZ,§§§ YIH-SHARNG CHEN,¶¶¶

LEONARDO SALAZAR,∥∥∥ AND GLENN WHITMAN###

REVIEWERS: Hergen Buscher,\*\*\*\* Rodrigo Diaz,†††† Thomas Mueller,‡‡‡‡ AND Alain Combes,§§§§

#### Table 8. Clinical Monitoring During Venoarterial Extracorporeal Membrane Oxygenation

#### Invasive arterial blood pressure monitoring/right radial artery

- Pulse pressure—measure of native contractility vs. ECMO blood flow
- Oxygen saturation—measure of oxygenation in proximal aortic arch/detection of differential oxygenation

#### Pulse oximetry/right hand

 Oxygen saturation—measure of oxygenation in proximal aortic arch/detection of differential oxygenation

#### Pulmonary artery catheter

- Detect elevated left-sided filling pressure
- Support indication for adjunct LV unloading
- Continuous cardiac output monitoring as indication of residual pulmonary artery flow (alternatively, residual pulmonary artery flow can be monitored by measuring end-tidal CO<sub>2</sub>)

#### **Echocardiography**

- Early cardiac diagnostics and identification of contraindications to VA ECMO
- Visualization of proper vascular access and guidance cannulation
- Optimal tailoring of ECMO support
- Serial assessment of hemodynamic and cardiac conditions
- Cardiac assessment during weaning trial

#### Electrocardiography

- Consider continuous, multilead electrocardiographic monitoring NIRS
- Monitoring of limb (single and bilateral comparison) and brain perfusion



## **ELSO Interim Guidelines for Venoarterial Extracorporeal Membrane Oxygenation in Adult Cardiac Patients**

ROBERTO LORUSSOO,\* KIRAN SHEKAR,† GRAEME MACLARENO,‡ MATTHIEU SCHMIDT,§ VINCENT PELLEGRINO,¶
BART MEYNS¶ JONATHAN HAFT,# LEEN VERCAEMST,¶ FEDERICO PAPPALARDO,\*\* CHRISTIAN BERMUDEZ,††
JAN BELOHLAVEKO,‡‡ XIAOTONG HOU,§§ UDO BOEKEN,¶¶ ROBERTO CASTILLO,¶¶ DIRK W. DONKERO,##\*\*\*\*
DARRYL ABRAMS,††† MARCO RANUCCI,‡‡‡ KASIA HRYNIEWICZ,§§§ IVAN CHAVEZ,§§§ YIH-SHARNG CHEN,¶¶
LEONARDO SALAZAR,¶¶¶ AND GLENN WHITMAN###
REVIEWERS: Hergen Buscher,\*\*\*\* Rodrigo Diaz,†††† Thomas Mueller,‡‡‡‡ and Alain Combes,§§§§

## Criteria to be used for the assessment of LV unloading need

Method	Factor		Grade of severity					
Arterial line								
	Arterial Pulsatility	Mild weakness	Moderate weakness	Almost Pulseles				
Central venous Line								
	ScvO <sub>2</sub>	75-55%	55-45%	<45%				
	CVP	8-12 mmHg	12-16 mmHg	> 20 mmHg				
Echocardiogram								
	AV	Opening every 2 bpm	Opening every 3-4 bpm	Closure				
	LV distension	Mild	Moderate	Severe				
	LA distension	Mild	Moderate	Severe				
	"Smoke like" effect	Mild	Moderate	Severe				
	IVC dilatation1	1.5 to 2.5 cm	>2.5 cm	>2.5 cm				
	IVC collapse <sup>2</sup>	<50%	<50%	No change				
Swan Ganz Catheter								
	PCWP	13-18 mmHg	18-25 mmHg	>25 mmHg				
Chest X-ray								
	Congestion <sup>3</sup>	Alveolar edema	Interstitial edema	Redistribution				

ScvO<sub>2</sub>: central venous blood oxygen saturation; CVP: central venous pressure, AV: aortic valve; bpm: beats per minute; LV: left ventricle; LA: left atria. PCWP: post capillary wedge pressure.

Less-Invasive LV-Unloading Maneuvers To Be Applied

IABP + Less-Invasive LV Unloading Maneuvers To Be Applied

Invasive Catheter-Based LV-Unloading Maneuvers To Be Applied ASAIO Journal 2021 Guidelines

## **ELSO Interim Guidelines for Venoarterial Extracorporeal Membrane Oxygenation in Adult Cardiac Patients**

ROBERTO LORUSSOO,\* KIRAN SHEKAR,† GRAEME MACLARENOO,‡ MATTHIEU SCHMIDT,§ VINCENT PELLEGRINO,¶
BART MEYNS¶ JONATHAN HAFT,# LEEN VERCAEMST, ¶ FEDERICO PAPPALARDO,\*\* CHRISTIAN BERMUDEZ,††
JAN BELOHLAVEKO,‡‡ XIAOTONG HOU,§§ UDO BOEKEN,¶¶ ROBERTO CASTILLO, ¶ DIRK W. DONKEROO,##\*\*\*\*
DARRYL ABRAMS,††† MARCO RANUCCI,‡‡‡ KASIA HRYNIEWICZ,§§§ VIAN CHAVEZ,§§§ YIH-SHARNG CHEN,¶¶¶

LEONARDO SALAZAR, ¶ ¶ ¶ AND GIENN WHITMAN;###

REVIEWERS: Hergen Buscher,\*\*\*\* Rodrigo Diaz, ++++ Thomas Mueller, ++++ AND Alain Combes, \$\frac{8}{5}\frac{8}{5}

## Table 4. Options, Procedures, and Related Efficacy Potentially Available to Pursue or Favoring Left Ventricular Unloading During Venoarterial Extracorporeal Life Support

Type of Procedure	Efficacy
Less-invasive maneuvers	
Reduced ECMO flow	$\sqrt{\sqrt{\sqrt{1}}}$
Inotropes	$\sqrt{}$
Vasodilation	$\sqrt{}$
Increased PEEP	$\sqrt{}$
Diuretics	√
Invasive (catheter-based) maneuvers	•
Trans-aortic suction device	
Impella	$\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{$
Pulsatile trans-aortic suction device	$\sqrt{\sqrt{\sqrt{1}}}$
Atrial septostomy	<b>√√√ - √√√√</b>
Left ventricular venting through the apex	$\sqrt{\sqrt{1}}$
Left ventricular venting through the mitral valve	$\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{$
Pulmonary artery venting	$\sqrt{\sqrt{1}}$
IABP	$\sqrt{}$
Tran-septal atrial cannula	$\sqrt{\sqrt{1}}\sqrt{1}$
Additional venous cannula	√√
Central ECLS	$\sqrt{}$

## ELSO Interim Guidelines for Venoarterial Extracorporeal Membrane Oxygenation in Adult Cardiac Patients

ROBERTO LORUSSO®,\* KIRAN SHEKAR,† GRAEME MACLAREN®,‡ MATTHIEU SCHMIDT,§ VINCENT PELLEGRINO,¶
BART MEYNS|| JONATHAN HAFT,# LEEN VERCAEMST,|| FEDERICO PAPPALARDO,\*\* CHRISTIAN BERMUDEZ,††
JAN BELOHLAVEK®,‡‡ XIAOTONG HOU,§§ UDO BOEKEN,¶¶ ROBERTO CASTILLO,||| DIRK W. DONKER®,##\*\*\*
DARRYL ABRAMS,††† MARCO RANUCCI,‡‡‡ KASIA HRYNIEWICZ,§§§ IVAN CHAVEZ,§§§ YIH-SHARNG CHEN,¶¶¶
LEONARDO SALAZAR,||||| AND GLENN WHITMAN###
REVIEWERS: Hergen Buscher,\*\*\*\* Rodrigo Diaz,†††† Thomas Mueller,‡‡‡‡ and Alain Combes,§§§§

Table 10. Major Complications of Venoarterial Extracorporeal Membrane Oxygenation and Suggested Management

Complication	Management
Malpositioning of cannula	Routine use of ultrasound/fluoroscopy for cannulation procedure
Ischemia of cannulated leg	Prophylactic use of small antegrade perfusion cannula,
	NIRS monitoring of calf muscle before, during and after VA ECMO oximetry, pulse Doppler of cannulated leg
Deep vein thrombosis of	Adequate anticoagulation during and after VA ECMO,
femoral/caval vein	Ultrasound control of vessels after decannulation
Overloading of LV	Reduce MAP to lowest acceptable value
•	Use a small dose of inotropes, avoid vasopressors if possible
	Use PAC and end-tidal CO <sub>2</sub> for monitoring of pulmonary perfusion
	Regular echocardiography 2
	Venting of LV when indicated (see proper table)
Differential oxygenation	Monitoring of BGA and saturation on right arm
	NIRS monitoring of the brain and lower limbs
	Optimize ventilation
	VAV cannulation only if necessary
Lower body	BGA post membrane after every change in ECMO settings
hyperoxemia/hypocapnia	Adjust gas flow and blender settings to achieve Normocapnia and slight hyperoxemia (150 mm Hg) after the oxygenator
Device clotting	Adequate anticoagulation
	Regular maintenance by control of aPTT or ACT, D-Dimers, trans-membrane pressure and gas transfer capacity—If relevant, timely system replacement
Hemorrhage	Adequate anticoagulation (reduced or stop heparin administration in case of excessive bleeding or life-threatening hemorrhage)
	Regular control of aPTT or ACT, platelets, fibrinogen
	NIRS monitoring of brain
	Avoid every unnecessary invasive procedure

## 2020 EACTS/ELSO/STS/AATS Expert Consensus on Post-Cardiotomy Extracorporeal Life Support in Adult Patients



Roberto Lorusso, MD, PhD, Chairperson,\* Glenn Whitman, MD, Chairperson,\* Milan Milojevic, MD, PhD,\* Giuseppe Raffa, MD, PhD, David M. McMullan, MD, Udo Boeken, MD, PhD, Jonathan Haft, MD, Christian A. Bermudez, MD, Ashish S. Shah, MD, and David A. D'Alessandro, MD

## Recommendations for ECLS Modes and Configurations

Recommendations

Class<sup>a</sup> Level<sup>b</sup>

Peripheral cannulation approach should be considered in patients with PCS and for V-A ECLS in the presence of LV or biventricular failure. 41,43-45


IIa B

#### ADULT: MECHANICAL CIRCULATORY SUPPORT

## Peripheral versus central extracorporeal membrane oxygenation for postcardiotomy shock: Multicenter registry, systematic review, and meta-analysis



Giovanni Mariscalco, MD, PhD,<sup>a</sup> Antonio Salsano, MD, PhD,<sup>b</sup> Antonio Fiore, MD,<sup>c</sup> Magnus Dalén, MD, PhD,<sup>d</sup> Vito G. Ruggieri, MD, PhD,<sup>e</sup> Diyar Saeed, MD,<sup>f</sup> Kristján Jónsson, MD, PhD,<sup>g</sup> Giuseppe Gatti, MD,<sup>h</sup> Svante Zipfel, MD,<sup>i</sup> Angelo M. Dell'Aquila, MD,<sup>j</sup> Andrea Perrotti, MD, PhD,<sup>k</sup> Antonio Loforte, MD, PhD,<sup>1</sup> Ugolino Livi, MD,<sup>m</sup> Marek Pol, MD,<sup>n</sup> Cristiano Spadaccio, MD,<sup>o</sup> Matteo Pettinari, MD,<sup>p</sup> Sigurdur Ragnarsson, MD, PhD,<sup>q</sup> Khalid Alkhamees, MD,<sup>r</sup> Zein El-Dean, MRCS, LLM,<sup>a</sup> Karl Bounader, MD,<sup>s</sup> and Fausto Biancari, MD, PhD,<sup>tu</sup> the PC-ECMO group\*



Doubly robust estimates with inverse probability treatment weighting by propensity score

#### ADULT: MECHANICAL CIRCULATORY SUPPORT

#### Peripheral versus central extracorporeal membrane oxygenation for postcardiotomy shock: Multicenter registry, systematic review, and meta-analysis



Giovanni Mariscalco, MD, PhD, a Antonio Salsano, MD, PhD, Antonio Fiore, MD, C Magnus Dalén, MD, PhD, d Vito G. Ruggieri, MD, PhD, e Diyar Saeed, MD, f Kristján Jónsson, MD, PhD, g Giuseppe Gatti, MD, h Svante Zipfel, MD, Angelo M. Dell'Aquila, MD, Andrea Perrotti, MD, PhD, h Antonio Loforte, MD, PhD, Ugolino Livi, MD, Marek Pol, MD, Cristiano Spadaccio, MD, Cristiano Sp Matteo Pettinari, MD, PSigurdur Ragnarsson, MD, PhD, Khalid Alkhamees, MD, Zein El-Dean, MRCS, LLM, a Karl Bounader, MD, and Fausto Biancari, MD, PhD, tu the PC-ECMO group\*

	Periph	neral	Cent	tral				Weight	Weight
Study	Events	Total	Events	Total	Risk Ratio	RR	95% CI	(fixed)	(random)
Ko et al. 2002 <sup>5</sup>	45	61	11	15		1.01	[0.72; 1.41]	2.6%	3.2%
Rastan et al. 2010 <sup>6</sup>	154	203	235	314	<del>"-</del>	1.01	[0.92; 1.12]	26.7%	30.0%
Pokersnik et al. 2012 <sup>7</sup>	22	32	11	17	<u> </u>	1.06	[0.70; 1.62]	2.1%	2.1%
Unosowa et al. 20128	11	32	7	15		0.74	[0.36; 1.52]	1.4%	0.7%
Mikus et al. 20139	3	7	4	7		0.75	[0.26; 2.18]	0.6%	0.3%
Loforte et al. 2014 <sup>10</sup>	31	62	32	56	<del> </del>	0.88	[0.62; 1.23]	4.9%	3.3%
Papadopoulos et al. 2015 <sup>11</sup>	225	324	27	36		0.93	[0.76; 1.13]	7.0%	8.8%
Zhao et al. 2015 <sup>12</sup>	15	23	1	1		0.66	[0.49; 0.88]	0.4%	4.4%
Khorsandi et al. 2016 <sup>13</sup>	6	9	9	14		1.04	[0.57; 1.90]	1.0%	1.0%
Mazzeffi et al. 2016 <sup>14</sup>	5	9	11	14		0.71	[0.37; 1.35]	1.2%	0.9%
Biancari et al. 2017 <sup>15</sup>	56	89	39	59	- <del>1</del>	0.95	[0.75; 1.21]	6.8%	6.2%
Guihaire et al. 2017 <sup>16</sup>	49	78	9	14	<del>- }</del>	0.98	[0.64; 1.50]	2.2%	2.1%
Raffa et al. 2017 <sup>17</sup>	35	56	19	27	<del>}</del>	0.89	[0.65; 1.22]	3.7%	3.7%
Slottosh et al. 2017 <sup>18</sup>	52	72	19	28		1.06	[0.79; 1.43]	4.0%	4.3%
Zhong et al. 2017 <sup>19</sup>	16	29	2	7		1.93	[0.57; 6.52]	0.5%	0.3%
PC-ECMO Study 2018	327	536	176	245		0.85	[0.77; 0.94]	35.0%	28.6%
Fixed effects model		1622		869	<b>!</b>	0.93	[0.88; 0.99]	100.0%	
Random effects model					<b>→</b>	0.92	[0.87; 0.98]		100.0%
Test for overall effect: Fixed of Random effects $P = .011$		,	ı.	0.2 <b>Favor</b>	0.5 1 2 5				


Test for heterogeinity:  $\tau^2 = 0.0007$ ;  $\ell = 4\%$ ; P = .41

Favours Peripheral Favours Central In-hospital/30-day mortality

#### Meta-Analysis of the Outcome After Postcardiotomy Venoarterial Extracorporeal Membrane Oxygenation in Adult Patients

Fausto Biancari, MD, PhD\*,†,¹, Andrea Perrotti, MD‡,
Magnus Dalén, MD, PhD§, Mariapia Guerrieri, MS†,
Antonio Fiore, MD□, Daniel Reichart, MD□,
Angelo M. Dell'Aquila, MD, PhD\*\*, Giuseppe Gatti, MD††,
Tero Ala-Kokko, MD, PhD†‡, Eeva-Maija Kinnunen, MD, PhD\*,
Tuomas Tauriainen, MS®, Sidney Chocron, MD, PhD‡,
Juhani K.E. Airaksinen, MD, PhD\*, Vito G. Ruggieri, MD, PhD§§,
Debora Brascia, MD\*

#### Journal of Cardiothoracic and Vascular Anesthesia 2018;32:1175-1182



Original Article | Published: 03 June 2021

Predictors of Mortality in Patients Treated with Veno-Arterial ECMO for Cardiogenic Shock Complicating Acute Myocardial Infarction: a Systematic Review and Meta-Analysis

Shahmir Sohail ≅, Eddy Fan, Farid Foroutan, Heather J. Ross, Filio Billia & Ana Carolina Alba

Journal of Cardiovascular Translational Research (2021) | Cite this article

213 Accesses | 14 Altmetric | Metrics

72 studies (10,276 patients) were included with a pooled mortality estimate of 58 %.

With high confidence in estimates, failure to achieve **TIMI III flow** and **left main culprit** were identified as factors associated with higher mortality.

With low-moderate confidence, older age, high BMI, renal dysfunction, increasing lactate, prothrombin activity < 50%, VA-ECMO implantation after revascularization, and non-shockable ventricular arrythmias were identified as factors associated with mortality

#### Meta-Analysis of the Outcome After Postcardiotomy Venoarterial Extracorporeal Membrane Oxygenation in Adult Patients

Fausto Biancari, MD, PhD\*, 1, Andrea Perrotti, MD<sup>‡</sup>, Magnus Dalén, MD, PhD<sup>§</sup>, Mariapia Guerrieri, MS<sup>†</sup>, Antonio Fiore, MD<sup>||</sup>, Daniel Reichart, MD<sup>¶</sup>, Angelo M. Dell'Aquila, MD, PhD\*\*, Giuseppe Gatti, MD<sup>††</sup>, Tero Ala-Kokko, MD, PhD<sup>‡‡</sup>, Eeva-Maija Kinnunen, MD, PhD<sup>‡</sup>, Tuomas Tauriainen, MS\*, Sidney Chocron, MD, PhD<sup>‡</sup>, Juhani K.E. Airaksinen, MD, PhD\*, Vito G. Ruggieri, MD, PhD<sup>§§</sup>, Debora Brascia, MD\*

#### Journal of Cardiothoracic and Vascular Anesthesia 2018;32:1175–1182

Table 3
Pooled Rates of Early Outcomes

Outcomes	No. of Studies	No. of Patients	Proportion/Mean (95% CI)	$I^2$
Hospital survival, %	31	2,986	36.1 (31.5-40.8)	84%
Weaning from VA-ECMO, %	24	2,049	59.5 (54.6-64.3)	77%
Reoperation for bleeding, %	18	1,779	42.9 (34.2-51.5)	93%
RBC units transfused	11	1,241	17.7 (13.3-22.1)	99%
Major neurological event, %	16	1,736	11.3 (7.8-14.8)	79%
Limb ischemia, %	16	1,909	10.8 (8.0-13.5)	70%
Lower limb amputation, %	5	330	1.1 (0.0-2.3)	0%
Deep sternal wound infection/mediastinitis, %	4	490	14.7 (4.0-25.4)	92%
Renal replacement therapy, %	19	1,979	47.1 (38.9-55.2)	92%
Ventricular assist device, %	21	1,685	2.3 (1.3-3.4)	57%
Heart transplantation, %	21	1,685	1.9 (1.0-2.8)	50%
Intensive care unit stay, d	10	589	13.3 (10.2-16.4)	95%
In-hospital stay, d	9	1,154	22.5 (17.7-27.3)	95%

#### Meta-Analysis of the Outcome After Postcardiotomy Venoarterial Extracorporeal Membrane Oxygenation in Adult Patients

Fausto Biancari, MD, PhD\*,†,¹, Andrea Perrotti, MD‡,
Magnus Dalén, MD, PhD§, Mariapia Guerrieri, MS†,
Antonio Fiore, MD□, Daniel Reichart, MD□,
Angelo M. Dell'Aquila, MD, PhD\*\*, Giuseppe Gatti, MD††,
Tero Ala-Kokko, MD, PhD†‡, Eeva-Maija Kinnunen, MD, PhD\*,
Tuomas Tauriainen, MS®, Sidney Chocron, MD, PhD†,
Juhani K.E. Airaksinen, MD, PhD\*, Vito G. Ruggieri, MD, PhD§§,
Debora Brascia, MD\*

Journal of Cardiothoracic and Vascular Anesthesia 2018;32:1175–1182

One-year survival rate was 30.9% (95% CI 24.3-37.5)


#### European Heart Journal

## **Acute Cardiovascular Care**

## Five-year survival after post-cardiotomy venoarterial extracorporeal membrane oxygenation

Fausto Biancari █, Andrea Perrotti, Vito G Ruggieri, Giovanni Mariscalco, Magnus Dalén, Angelo M Dell'Aquila, Kristján Jónsson, Sigurdur Ragnarsson, Dario Di Perna, Karl Bounader ... Show more

European Heart Journal. Acute Cardiovascular Care, Volume 10, Issue 6, August 2021,



Recommendation	ıs foı	<sup>.</sup> Education	and	Training

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
Didactic and water drills are recommended as a routine and repetitive part of ECLS training for providers. 197	I	В
ECLS simulation is recommended for ECLS multispecialty teams as well as individual specialists. 195,202	_	В
ECLS simulation is recommended for teambased learning specialties. 197-201	I	В

<sup>&</sup>lt;sup>a</sup>Class of recommendation; <sup>b</sup>Level of evidence.

ECLS, extracorporeal life support.